Global Search

Hide Filters

Showing 1672 results

Press release / Jul 23, 2018

Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke

Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million…
Press release / Apr 21, 2015

Novartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local communities

More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities Community Partnership Day symbolizes the company'…
Press release / Jul 27, 2015

Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt

Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees New trustees also include Professor Peter Piot of the London School…
Press release / Jun 22, 2016

Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
Press release / Oct 04, 2018

Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges

Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek…
Press release / Apr 05, 2022

Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility

Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
Press release / Nov 15, 2016

New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths

Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril[1]…
Press release / Dec 04, 2018

Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data

PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients[1],[2] Ligelizumab (QGE031), a monoclonal antibody…
Press release / Oct 19, 2018

Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC

Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small…
Press release / Oct 30, 2020

Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises

Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in EuropeClinical data showed that use of Adakveo led to a…